Treatments ERT

MPS I

Aldurazyme, administered once weekly, is approved in more than 60 countries worldwide, including the United States and across Europe for long-term enzyme replacement therapy in patients with a confirmed diagnosis of MPS I, to treat the non-neurological manifestations of the disease. Aldurazyme was developed by BioMarin and SanofiGenzyme under a joint venture agreement that assigns commercial manufacturing responsibilities to BioMarin, and worldwide sales and marketing responsibilities to SanofiGenzyme.

Additional information can be obtained at www.aldurazyme.com or by contacting SanofiGenzyme at 800-745-4447.

MPS II

Elaprase is a long-term enzyme replacement therapy for patients with a confirmed diagnosis of MPS II and has been approved for use in the U.S., Canada and many countries in Europe. Elaprase was developed and is produced by Shire Pharmaceuticals and is given as weekly infusions.

Additional information can be obtained at www.shire.com or by contacting OnePathSM
toll free 866-888-0660. OnePath provides assistance with insurance, product access, treatment centers and education about Elaprase and MPS II.

MPS IVA

Vimizim™ (elosulfase alfa), developed by BioMarin Pharmaceutical Inc. is the enzyme replacement therapy for individuals with MPS IVA (Morquio A syndrome.)  Vimizim is administered weekly via intravenous infusion.

BioMarin will offer support to patients through its BioMarin Patient & Physician Support (BPPS) team. Through BPPS, patients receive live, personalized support by a specialized case manager who will research insurance coverage and alternative benefit options. BPPS will help patients obtain coverage and minimize out-of-pocket expenses and find alternative financial assistance for treatment. To reach a BPPS case manager, please call 866-906-6100. For more information about VIMIZIM, please visit www.VIMIZIM.com.

MPS VI

Naglazyme is the enzyme replacement therapy for individuals with a confirmed diagnosis of MPS VI and has been approved for use in the U.S. and in many European countries. Developed and produced by BioMarin Pharmaceutical, Inc, Naglazyme has been shown to improve walking and stair-climbing capacity.

For more information, please contact BioMarin Patient and Physician Support (BPPS) at bpps@bmrn.com or 866-906-6100.